Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 5/20 | 0.45 |
| ▸ | MMP13 | P45452 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2206562 | 1.00 | PARP1 (0.48) | PARP1MAOAMMP8MMP13GAA | |
| SCHEMBL2206278 | 0.85 | PARP1 (0.47) | PARP1MAOAMMP8MMP13GAA | |
| SCHEMBL2206281 | 0.85 | PARP1 (0.47) | PARP1MAOAMMP8MMP13GAA | |
| SCHEMBL2205699 | 0.83 | POLB (0.40) | — | |
| SCHEMBL2205696 | 0.83 | POLB (0.40) | — | |
| SCHEMBL2207669 | 0.83 | KCNH2 (0.44) | MAOATSHR | |
| SCHEMBL2207677 | 0.83 | KCNH2 (0.44) | MAOATSHR | |
| SCHEMBL5260081 | 0.80 | PARP1 (0.58) | PARP1MAOAMMP8MMP13GAA | |
| SCHEMBL5260082 | 0.80 | PARP1 (0.58) | PARP1MAOAMMP8MMP13GAA | |
| SCHEMBL2208706 | 0.79 | MMP8 (0.43) | PARP1MAOAMMP8MMP13GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888574-B1 | NEW ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | EP | claimed |
| US-20080280888-A1 | Antibiotics Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-13 | — | — | US | claimed |
| US-7981886-B2 | Antibiotics derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-07-19 | — | — | US | disclosed |
| EP-1888574-B1 | NEW ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080280888-A1 | Antibiotics Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280888-A1 | Antibiotics Derivatives | NR4A1, NR2C2, NR4A3 | PARP1 3414/4885MAOA 2201/4885MMP8 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.